Rosemary Harrison - Nov 17, 2021 Form 4 Insider Report for Trillium Therapeutics Inc. (TRIL)

Role
Title: Senior Vice President, Corporate Development and Strategy
Signature
/s/ James Parsons, Attorney-in-Fact
Stock symbol
TRIL
Transactions as of
Nov 17, 2021
Transactions value $
$0
Form type
4
Date filed
11/19/2021, 12:30 PM
Next filing
Jan 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRIL Common Shares Disposed to Issuer -75 -100% 0 Nov 17, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRIL Stock Option (Right to Buy) Disposed to Issuer $0 -180K -100% $0.00* 0 Nov 17, 2021 Common Shares 180K $14.11 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Rosemary Harrison is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.

Remarks:

Title: Senior Vice President, Corporate Development and Strategy